SSAs can also inhibit the growth of neuroendocrine tumors through mechanisms that include the activation of somatostatin receptors (SSTRs) inhibiting adenylate cyclase and ultimately suppressing the ERK signaling pathway. This evidence concerns the gene ADCY1 and neuroendocrine neoplasm.